Levetiracetam in the Prophylaxis of Migraine With Aura
Authors:
- Filippo BrighinaFilippo Brighina
- Antonio PalermoAPAntonio Palermo
- Antonina AloisioAAAntonina Aloisio
- Margherita FrancoliniMFMargherita Francolini
- Giuseppe GigliaGiuseppe Giglia
- Brigida FierroBFBrigida Fierro
- 1 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 29 (6) , 338-342
Abstract
To evaluate the efficacy of levetiracetam as prophylactic treatment for migraine with aura with high frequency of attacks. Migraine with aura with high frequency of attacks could represent a very demanding therapeutic problem. Efficacy of the antiepileptic drug, lamotrigine, has been reported in this form of migraine. Levetiracetam is a new antiepileptic drug with an excellent tolerability profile. Mechanisms of action of this drug remain largely unknown, but recently, it has been shown to exert inhibitory effects on neuronal-type calcium channels. We performed a small open-label trial treating 16 patients affected by migraine with aura with high frequency of attacks. After a 1-month run-in period, patients were treated with levetiracetam at a dosage of 1000 mg/d for 6 months. The number of attacks per month was significantly reduced during the first month (compared with run-in; P < 0.001), and it was reduced further during the second (second month vs first month; P < 0.001) and the third months (third month vs second month; P < 0.001) of the treatment. This improvement persisted unchanged for the remaining 3 months of treatment. In 7 (44%) of the 16 patients, the attacks were completely abolished after 3 months of treatment. Severity of headache and duration of headache and aura were also significantly reduced at the third and sixth months of treatment (P < 0.001). Levetiracetam was well tolerated (6 patients complained of slight dizziness, nervousness, and somnolence). Levetiracetam seems to be a safe and effective treatment for migraine with aura. Controlled trials are needed to confirm the observed results.Keywords
This publication has 12 references indexed in Scilit:
- Effects of N-, P/Q- and L-type Calcium Channel Blockers on Nociceptive Neurones of the Trigeminal Nucleus with Input from the DuraCephalalgia, 2004
- Blockade of voltage-gated calcium channels in rat inhibits repetitive cortical spreading depressionNeuroscience Letters, 2002
- Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine modelNature Medicine, 2002
- Selective Blockade of N‐Type Calcium Channels by LevetiracetamEpilepsia, 2002
- Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slicesNeuroscience Letters, 2001
- Levetiracetam does not modulate neuronal voltage-gated Na and T-type Ca currentsSeizure: European Journal of Epilepsy, 2001
- Subclinical cerebellar impairment in the common types of migraine: A three‐dimensional analysis of reaching movementsAnnals of Neurology, 2001
- Neuromuscular transmission in migraineNeurology, 2001
- Effectiveness of Lamotrigine in the Prophylaxis of Migraine with Aura: an Open Pilot StudyCephalalgia, 1999
- Familial Hemiplegic Migraine and Episodic Ataxia Type-2 Are Caused by Mutations in the Ca2+ Channel Gene CACNL1A4Cell, 1996